美国 - 英文 - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: -   atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. -   use of atazanavir/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are asso

美国 - 英文 - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: • atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [ see use in specific populations ( 8.4) ].  • use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [ see microbiology ( 12.4)] . atazanavir capsules are contraindicated: • in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens- johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [ see warnings and precautions (

肯尼亚 - 英文 - Pharmacy and Poisons Board

atazanavir sulfate and ritonavir tablets 300mg… - tablet - atazanavir sulfate and ritonavir tablets 300mg… - antivirals for systemic use: combinations of

坦桑尼亚 - 英文 - Tanzania Medicinces & Medical Devices Authority

lupin limited, india - atazanavir , ritonavir - tablets - atazanavir sulfate 300 mg and ritonavir 100 mg

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 341.71 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 341.71 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 227.81 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 227.81 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).